Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of rVSV-ZEBOV-GP Ebola Vaccine in Healthy Adults
NCT02283099Phase 1Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2014
- Primary completion
- Nov 2015
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (3 cohorts), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Number of adverse events associated with the rVSVΔ-ZEBOV-GP vaccine. Started Nov 2014; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02283099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283099.